5th International
Antibody Validation Meeting
- University of Bath
- 09/09/25 - 11/09/25
- TBC Speakers
The event
A unique meeting which aims to bring together scientists from academia, the pharmaceutical / biotech sector and antibody suppliers in order to discuss best practices in research antibody validation and help improve antibody validation for the life science community.
Why come?
Join us in the beautiful city of Bath to help drive progress in antibody validation. The 2025 meeting will include discussion panels, poster sessions, a meeting dinner and a series of talks.
If you're interested in submitting an abstract or poster for the meeting, you can do so here. Submissions close on the 30th June.
Register now, or for further enquiries about registration, just drop us an email.
Confirmed speakers
Danielle Callahan
Proteintech, US
More information to come.
Elisia Clark
The Michael J. Fox Foundation, US
Dr. Elisia Clark, Senior Scientist at MJFF, is part of the Preclinical Research Tools Program, driving efforts to develop and validate high-quality research tools to advance Parkinson's research. Through partnerships, this program has resulted in 50+ novel antibodies to date.
Carly Dix
AstraZeneca, UK
Dr Carly Dix is Associate Director at AstraZeneca UK, leading the Affinity Reagents Team within Biologics Engineering. Since joining AZ in 2015 Carly has worked on the selection, generation and validation of antibodies and has an interest in antibody validation best practice.
Johan Duchêne
Ludwig Maximilian University, Germany
Dr Johan Duchêne Senior Lecturer in Immunology, investigates the chemokine system in cardiovascular disease. To accurately study the roles of chemokines and their receptors in pathology, access to specific antibodies is essential. His group is committed to validating the specificity of these reagents before using them in their research.
Myriam Duckely
Novartis, CH
Myriam Duckely, Ph.D., is a Senior Principal Scientist at Novartis, specializing in drug discovery targeting human GPCRs and transporters. She is currently Program Director of FreeNovation, a philanthropic program.
Björn Forsström
Olink Proteomics, SE
More information to come.
Will Howat
Abcam, UK
Dr Will Howat is the VP of Validation and Technical Quality at Abcam. Abcam has a keen interest in antibody validation and ensuring quality is a key driver for future scientific publications.
Elena Ivanova
Regeneron, US
Elena Ivanova is the head of the pre-clinical histology core, specialized on IHC and IF Multiplex assays, serving all therapeutic areas at Regeneron.
Carl Laflamme
Antibody Characterization Group, UK
More information to come.
Thierry Le Bihan
Rapid Novor, Canada
More information to come.
Ulf Landegren
Uppsala University, SE
Ulf Landegren, Uppsala professor, develops molecular tools for nucleic acid and protein analysis. He's a member of EMBO and the Royal Swedish Academy, with 230+ publications and 55+ patents. His lab gave rise to companies like Olink and Navinci, and his tech is licensed by major biotech firms.
Deborah Moshinsky
Institute for Protein Innovation, US
Deborah is the Director of Antibody Characterization and Validation at the Institute for Protein Innovation (IPI). She earned her Ph.D. from MIT and held roles at various pharmaceutical companies including Pfizer and Novartis before co-founding Cell Assay Innovations.
Leticia Montoya
Thermo Fisher Scientific, US
More information to come.
Nidhi Nath
Bio-Techne, US
More information to come.
Roberto Polakiewicz
Cell Signaling Technology, US
Roberto has been Cell Signaling Technology's CSO since 2005. Before helping start CST in 1999, he was a scientist at New England Biolabs. He holds a PhD in molecular biology and completed a postdoctoral fellowship at the Whitehead Institute at MIT.
Andrea Radtke
Leica Microsystems, US
Dr. Andrea Radtke, is passionate about open science, she co-leads community antibody validation initiatives. Since August 2024, she has been a Principal Scientist at Leica Microsystems.
Jim Trimmer
UC Davis & NIH NeuroMab Facility, US
Dr. Trimmer, a UC Davis neuroscientist, develops antibodies for neuroscience research. With 200+ publications, he directs the NeuroMab Facility, working on highly characterized monoclonal and recombinant antibody production, hybridoma sequencing and more.
Michael Weiner
Precision BioTools, US
Dr. Michael P. Weiner developed key technologies, including QuikChange mutagenesis, next-gen DNA sequencing and emulsion PCR, and DNA barcoding Luminex beads. A serial entrepreneur, he has founded multiple biotech firms and holds over 50 patents.
Libby Wiseman
Astrazeneca, UK
Libby is an AstraZeneca Senior Scientist in the Translational Pathology group within Early Oncology Cancer Biomarker Development. She focuses on antibody validation, especially PTMs, and studies pre-analytical factors affecting labile biomarkers.
More Speakers TBC
Invited and Abstract Speakers
2 selected abstract speakers and more invited speakers to be confirmed.
The session chairs
Katarzyna Kmiecik
Alchemab Therapeutics, UK
More information to come.
Asel Sartbaeva
EnsiliTech, UK
More information to come.
Selected Session Chairs
TBC
More information to come.
Interested in becoming an AbVal meeting sponsor?
Get in touch for details about sponsorship opportunities, and other ways you can get involved!
We hope to see you at the next International Antibody Validation meeting.
